Lamivudine/nevirapine/zidovudine
Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a medication used to treat HIV/AIDS.[2] It is a fixed dose combination of lamivudine, nevirapine, and zidovudine.[2] It is either used by itself or along with other antiretrovirals.[2] It is a recommended treatment in those who are pregnant.[2] It is taken by mouth twice a day.[2]
| Combination of | |
|---|---|
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Nevirapine | non-nucleoside reverse transcriptase inhibitor |
| Zidovudine | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Duovir-N, Zidovex-LN, others[1] |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
The medication is generally well tolerated.[1] Side effects are those of the underlying medications.[2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.[1] Use is not recommended in those with significant liver problems.[1] Use in pregnancy and breastfeeding appear to be safe.[1] The combination tablet is typically not appropriate for children.[2]
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 8.54 to 18.94 USD a month as of 2014.[4] The combination is not commercially available in the United States as of 2018.[5]
References
- "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived (PDF) from the original on 20 December 2016. Retrieved 18 December 2016.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 157, 161. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Lamivudine + Zidovudine + Nevirapine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.